Clinical MedicineUpdated Aug 18, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from Cancer Discovery indicates that CTC and ctDNA analyses are pivotal for personalized medicine in oncology. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Cancer Discovery indicates that CTC and ctDNA analyses are pivotal for personalized medicine in oncology. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Proceedings of the National Academy of Sciences indicates that A combined ctDNA and protein marker liquid biopsy demonstrated improved sensitivity and specificity compared to individual markers. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Human Genomics indicates that NGS has significantly advanced ctDNA sequencing for liquid biopsies. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from British Journal of Cancer indicates that ctDNA analysis is valuable for detecting mutations related to cancer resistance and monitoring. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from Proceedings of the National Academy of Sciences indicates that A combined ctDNA and protein marker liquid biopsy demonstrated improved sensitivity and specificity compared to individual markers. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Human Genomics indicates that NGS has significantly advanced ctDNA sequencing for liquid biopsies. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.
Evidence from British Journal of Cancer indicates that ctDNA analysis is valuable for detecting mutations related to cancer resistance and monitoring. This is tracked as a clinical because it changes how Liquid Biopsy for Early Cancer Detection is understood, validated, or applied.